Deucravacitinib With Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis

BACKGROUND: To assess the effectiveness, safety, and quality of life in patients who received topical calcipotriene/betamethasone dipropionate (C/BD) foam added to oral deucravacitinib for treating moderate to severe, chronic plaque psoriasis. METHODS: In this prospective, open-label, single-center study, adults (≥18 years of age) with psoriasis (physician global assessment [PGA] ≥3, body surface area [BSA] ≥10%, and psoriasis area severity index [PASI] ≥12) took deucravacitinib (6 mg daily) for 8 weeks. At week 8, patients who achieved PASI 75 continued on deucravacitinib alone up to week 24; PASI 25-74 used daily, C/BD for 4 weeks; and